Trials / Completed
CompletedNCT00262288
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
A Phase II/III Study of the Efficacy and Safety of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Pharming Technologies B.V. · Industry
- Sex
- All
- Age
- 16 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this multi-center study is to explore the efficacy, safety, tolerability and pharmacokinetics/pharmacodynamics of recombinant human C1 inhibitor in the treatment of acute attacks in patients with hereditary angioedema.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | i.v. recombinant human C1 inhibitor |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2007-01-01
- Completion
- 2007-01-01
- First posted
- 2005-12-06
- Last updated
- 2013-02-22
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT00262288. Inclusion in this directory is not an endorsement.